Andrew Kuykendall, MD, discusses the background, methods, and design of a phase 2 study which evaluated fedratinib.

FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.

Kathryn Beckermann, MD, PhD, discusses the patient-reported outcomes for tivozanib plus nivolumab from the phase 3 TiNivo-2 ...

Bernstam, MD, discusses updated findings from the phase 1 TROPION-PanTumor01 study of datopotamab deruxtecan-dlnk in heavily ...

Panelists discuss how CARTITUDE-4 demonstrated superior progression-free survival and overall response rates with ...

The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...

In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

Avelumab maintenance with axitinib interruption was feasible in metastatic renal cell carcinoma responders, according to ...

The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...

Over 90% adherence to relugolix in patients with Medicare with prostate cancer for 24 months supports its use as androgen ...

Hany Elmariah, MD, discussed the safety profile of fedratinib and its evolving role in the post-transplant setting for patients with myeloproliferative neoplasms.